Extension Study to the "Open-label Phase I Study Evaluating the Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs - The COOPERATE-1 Study".
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2019
At a glance
- Drugs Everolimus (Primary) ; Pasireotide (Primary)
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions
- Acronyms COOPERATE-1
- Sponsors Novartis Pharmaceuticals
- 13 Apr 2019 Status changed from active, no longer recruiting to completed.
- 13 Sep 2018 Planned primary completion date changed from 31 Dec 2018 to 1 May 2020.
- 11 May 2018 Planned primary completion date changed from 1 May 2020 to 31 Dec 2018.